Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group has reported positive topline results from a Phase III, multi-centre, randomised, double-blind equivalence trial of its biosimilar Secukinumab Injection for moderate to severe plaque psoriasis. The study, comparing the company’s fully human IgG1 monoclonal antibody directly with reference drug Cosentyx in Chinese patients, met its primary endpoint of PASI-75 response at Week 12 and demonstrated clinical equivalence in efficacy, along with a favourable and consistent safety profile. The outcome strengthens CSPC’s push into the high-value biologics and biosimilars segment, positioning the group to compete in China’s growing market for IL-17A inhibitors and potentially broadening its future revenue base in autoimmune and inflammatory diseases, subject to regulatory approvals.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company whose portfolio includes innovative and generic medicines, with a growing focus on biologics. Through its subsidiary CSPC Megalith Biopharmaceutical, the group is developing biosimilar monoclonal antibody therapies to address large chronic-disease markets such as psoriasis in China, where unmet demand for advanced biologic treatments remains significant.
Average Trading Volume: 121,043,821
Technical Sentiment Signal: Buy
Current Market Cap: HK$84.66B
For an in-depth examination of 1093 stock, go to TipRanks’ Overview page.